Clinical Trials Browser

Terminated × Triple Negative Breast Neoplasms × Fulvestrant × Clear all

NCT04726332 2024-05-14

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)

Phase 1 Terminated

BreastGynecologic

Carcinoma, Ovarian Epithelial, Neoplasms, Triple Negative Breast Neoplasms